Samjin Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Samjin Pharmaceuticals's earnings have been declining at an average annual rate of -22.9%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 9.6% per year. Samjin Pharmaceuticals's return on equity is 7.9%, and it has net margins of 8%.
Key information
-22.9%
Earnings growth rate
-25.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 9.6% |
| Return on equity | 7.9% |
| Net Margin | 8.0% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Samjin Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 274,032 | 21,894 | 89,197 | 3,658 |
| 31 Dec 21 | 250,070 | 28,404 | 79,937 | 2,582 |
| 30 Sep 13 | 189,385 | 5,567 | 85,764 | 0 |
| 30 Jun 13 | 190,107 | 3,508 | 87,109 | 0 |
Quality Earnings: A005500 has high quality earnings.
Growing Profit Margin: A005500's current net profit margins (8%) are lower than last year (11.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A005500's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: A005500's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A005500 had negative earnings growth (-22.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (34.6%).
Return on Equity
High ROE: A005500's Return on Equity (7.9%) is considered low.